Avita Medical raises FY 2026 revenue guidance to $92‑$94 million after strong Q3 growth
Avita Medical reported third‑quarter 2026 revenue of $26.1 million, up 53% year‑over‑year and 20% sequentially, driven by RECELL and Cohealyx sales. The company lifted its full‑year revenue outlook to $92 million‑$94 million, above the prior $86 million‑$89 million range, and said it expects cash‑flow breakeven in Q4. It also secured a $10 million credit facility to address going‑concern concerns.
Why it matters
The raised guidance expands the revenue target for investors by $3 million‑$5 million versus the prior outlook, and the anticipated cash‑flow breakeven could improve liquidity risk in the fourth quarter, according to the company’s commentary.
Key facts
- 1Q3 2026 revenue was $26.1 million, up 53% year‑over‑year and 20% from the second quarter. finance.yahoo.com
- 2U.S. RECELL revenue reached $22.4 million, about 20% above the second quarter. finance.yahoo.com
- 3Cohealyx revenue was $2.1 million, up approximately 21% from the second quarter. finance.yahoo.com
- 4Full‑year 2026 revenue guidance was raised to $92 million‑$94 million, from the prior $86 million‑$89 million range. finance.yahoo.com
- 5The company expects cash‑flow breakeven in the fourth quarter of 2026. finance.yahoo.com
- 6Avita Medical secured a $10 million credit facility to alleviate going‑concern doubts. finance.yahoo.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.